Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

NCT00702052 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Mantle- Cell

Interventions

DRUG: Everolimus

Sponsor

Novartis Pharmaceuticals